Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Decitabine for Immune Thrombocytopenia
NCT01568333Phase 2Completed
- Sponsor
- Shandong University
- Start
- Aug 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in immune thrombocytopenia (ITP), sponsored by Shandong University. Primary endpoint: Platelet count at 3 months. Started Aug 2015; status: completed.
02
Drugs
decitabine
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01568333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01568333.